Enveric Biosciences Inc Asset Resilience Ratio
Enveric Biosciences Inc asset resilience ratio. Enveric Biosciences Inc (ENVB) has an Asset Resilience Ratio of 0.75% as of March 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Enveric Biosciences Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Enveric Biosciences Inc (2007–2016)
Asset resilience ratio of Enveric Biosciences Inc from 2007 to 2016. This chart shows how Enveric Biosciences Inc's Asset Resilience Ratio has changed over time. Read Enveric Biosciences Inc (ENVB) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Enveric Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Enveric Biosciences Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $227.34K | 0.75% |
| Total Liquid Assets | $227.34K | 0.75% |
Asset Resilience Insights
- Limited Liquidity: Enveric Biosciences Inc maintains only 0.75% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Enveric Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Enveric Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Enveric Biosciences Inc Asset Resilience Ratio by Year (2007–2016)
Enveric Biosciences Inc asset resilience ratio by year from 2007 to 2016. The table below shows the annual Asset Resilience Ratio data for Enveric Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 0.21% | $82.91K | $39.51 Million | -0.39pp |
| 2015-12-31 | 0.60% | $82.91K | $13.83 Million | -61.71pp |
| 2007-12-31 | 62.30% | $1.00 Million | $1.61 Million | -- |
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage fo… Read more